| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Mariana P Torrente, Alan J Gelenberg, Kent E Vran. Boosting serotonin in the brain: is it time to revamp the treatment of depression? Journal of psychopharmacology (Oxford, England). vol 26. issue 5. 2013-01-21. PMID:22158544. |
boosting serotonin in the brain: is it time to revamp the treatment of depression? |
2013-01-21 |
2023-08-12 |
Not clear |
| Mariana P Torrente, Alan J Gelenberg, Kent E Vran. Boosting serotonin in the brain: is it time to revamp the treatment of depression? Journal of psychopharmacology (Oxford, England). vol 26. issue 5. 2013-01-21. PMID:22158544. |
abnormalities in serotonin systems are presumably linked to various psychiatric disorders including schizophrenia and depression. |
2013-01-21 |
2023-08-12 |
Not clear |
| Helen Bould, Nicola Wiles, John Potokar, Philip Cowen, David J Nutt, Tim J Peters, Glyn Lewi. Does baseline fatigue influence treatment response to reboxetine or citalopram in depression? An open label randomized controlled trial. Journal of psychopharmacology (Oxford, England). vol 26. issue 5. 2013-01-21. PMID:22223618. |
we conducted a secondary analysis of an rct in which patients with depression were randomly assigned to reboxetine (a noradrenaline reuptake inhibitor [nari]) or citalopram (a selective serotonin reuptake inhibitor [ssri]). |
2013-01-21 |
2023-08-12 |
Not clear |
| Daniella Johansson, Aki Falk, Monica M Marcus, Torgny H Svensso. Celecoxib enhances the effect of reboxetine and fluoxetine on cortical noradrenaline and serotonin output in the rat. Progress in neuro-psychopharmacology & biological psychiatry. vol 39. issue 1. 2013-01-21. PMID:22691715. |
interestingly, adjunct treatment with the anti-inflammatory drug celecoxib, a cyclo-oxygenase-2 (cox-2) inhibitor which blocks the pge(2)-production, has shown to enhance the efficacy of both reboxetine, a selective noradrenaline reuptake inhibitor, as well as fluoxetine, a selective serotonin reuptake inhibitor, in treatment-resistant depression. |
2013-01-21 |
2023-08-12 |
rat |
| Yan Li, Alan L Pehrson, David P Budac, Connie Sánchez, Maria Gulinell. A rodent model of premenstrual dysphoria: progesterone withdrawal induces depression-like behavior that is differentially sensitive to classes of antidepressants. Behavioural brain research. vol 234. issue 2. 2013-01-21. PMID:22789402. |
furthermore, these data do not support alterations in serotonin levels in the etiology of hormonally induced depression. |
2013-01-21 |
2023-08-12 |
Not clear |
| Saobo Le. Serotonergic modulation of Neural activities in the entorhinal cortex. International journal of physiology, pathophysiology and pharmacology. vol 4. issue 4. 2013-01-16. PMID:23320133. |
furthermore, the functions of serotonin in the ec may be implicated in parkinson's disease, alzheimer's disease and depression. |
2013-01-16 |
2023-08-12 |
Not clear |
| Gillian E Mead, Cheng-Fang Hsieh, Rebecca Lee, Mansur A Kutlubaev, Anne Claxton, Graeme J Hankey, Maree L Hacket. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. The Cochrane database of systematic reviews. vol 11. 2013-01-15. PMID:23152272. |
selective serotonin reuptake inhibitors (ssris) have been used for many years to manage depression. |
2013-01-15 |
2023-08-12 |
Not clear |
| Alan L Hudson, Maggie D Lalies, Peter Silverston. Venlafaxine enhances the effect of bupropion on extracellular dopamine in rat frontal cortex. Canadian journal of physiology and pharmacology. vol 90. issue 6. 2013-01-14. PMID:22512539. |
venlafaxine is recognised as an effective treatment for depression and is known to inhibit the reuptake of serotonin (5-ht) and noradrenaline (na). |
2013-01-14 |
2023-08-12 |
rat |
| Kyung Ran Kim, Hyun Cheol Chung, Eun Lee, Se Joo Kim, Kee Namkoon. Body image, sexual function and depression in Korean patients with breast cancer: modification by 5-HTT polymorphism. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer. vol 20. issue 9. 2013-01-09. PMID:22134442. |
the purpose of this study was to clarify how psychosocial factors (body image, sexuality, and social relationships) and genetic factors (functional polymorphism of the serotonin transporter-linked promoter region) influence depression. |
2013-01-09 |
2023-08-12 |
Not clear |
| Dora Zalai, Lilla Szeifert, Marta Nova. Psychological distress and depression in patients with chronic kidney disease. Seminars in dialysis. vol 25. issue 4. 2013-01-08. PMID:22809005. |
preliminary data indicate that some of the selective serotonin reuptake inhibitor agents and time-limited, manualized, structured psychotherapies can be safe and effective for treating depression in this population. |
2013-01-08 |
2023-08-12 |
Not clear |
| Yvet Kroeze, Huiqing Zhou, Judith R Homber. The genetics of selective serotonin reuptake inhibitors. Pharmacology & therapeutics. vol 136. issue 3. 2013-01-04. PMID:22944042. |
based on the fact that ssris increase extracellular monoamine levels in the brain, the monoamine hypothesis of depression was introduced, postulating that depression is associated with too low serotonin, dopamine and noradrenaline levels. |
2013-01-04 |
2023-08-12 |
Not clear |
| Johan Lundberg, Mikael Tiger, Mikael Landén, Christer Halldin, Lars Fard. Serotonin transporter occupancy with TCAs and SSRIs: a PET study in patients with major depressive disorder. The international journal of neuropsychopharmacology. vol 15. issue 8. 2012-12-28. PMID:22243688. |
serotonin transporter (5-htt) occupancy was estimated during treatment with tca, ssri and mirtazapine in 20 patients in remission from depression. |
2012-12-28 |
2023-08-12 |
Not clear |
| Pascal Bonaventure, Christine Dugovic, Michelle Kramer, Peter De Boer, Jaskaran Singh, Sue Wilson, Kirk Bertelsen, Jianing Di, Jonathan Shelton, Leah Aluisio, Lisa Dvorak, Ian Fraser, Brian Lord, Diane Nepomuceno, Abdellah Ahnaou, Wilhelmus Drinkenburg, Wenying Chai, Curt Dvorak, Steve Sands, Nicholas Carruthers, Timothy W Lovenber. Translational evaluation of JNJ-18038683, a 5-hydroxytryptamine type 7 receptor antagonist, on rapid eye movement sleep and in major depressive disorder. The Journal of pharmacology and experimental therapeutics. vol 342. issue 2. 2012-12-21. PMID:22570363. |
in rodents 5-hydroxytryptamine type 7 (5-ht(7)) receptor blockade has been shown to be effective in models of depression and to increase the latency to rapid eye movement (rem) sleep and decrease rem duration. |
2012-12-21 |
2023-08-12 |
mouse |
| Kimberly A Yonkers, Errol R Norwitz, Megan V Smith, Charles J Lockwood, Nathan Gotman, Edward Luchansky, Haiqun Lin, Kathleen Belange. Depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. Epidemiology (Cambridge, Mass.). vol 23. issue 5. 2012-12-21. PMID:22627901. |
depression and serotonin reuptake inhibitor treatment as risk factors for preterm birth. |
2012-12-21 |
2023-08-12 |
Not clear |
| James A Blumentha. New frontiers in cardiovascular behavioral medicine: comparative effectiveness of exercise and medication in treating depression. Cleveland Clinic journal of medicine. vol 78 Suppl 1. 2012-12-17. PMID:21972328. |
the standard therapy for depression is pharmacologic treatment, often with second-generation antidepressants such as selective serotonin reuptake inhibitors. |
2012-12-17 |
2023-08-12 |
Not clear |
| J L Pawluski, I Rayen, N A Niessen, S Kristensen, E L van Donkelaar, J Balthazart, H W Steinbusch, T D Charlie. Developmental fluoxetine exposure differentially alters central and peripheral measures of the HPA system in adolescent male and female offspring. Neuroscience. vol 220. 2012-12-14. PMID:22728102. |
selective serotonin reuptake inhibitors (ssris) are commonly used to treat maternal depression. |
2012-12-14 |
2023-08-12 |
rat |
| Shuken Boku, Takeshi Inoue, Hiroshi Honma, Hiroshi Honma, Shin Nakagawa, Tsukasa Koyam. Olanzapine augmentation of milnacipran for stage 2 treatment-resistant major depression: an open study. Human psychopharmacology. vol 26. issue 3. 2012-12-13. PMID:21638328. |
olanzapine augmentation of fluoxetine, a selective serotonin reuptake inhibitor, is an effective augmentation therapy for treatment-resistant depression (trd). |
2012-12-13 |
2023-08-12 |
Not clear |
| Csaba Juhász, Diane C Chugani, Geoffrey R Barger, William J Kupsky, Pulak K Chakraborty, Otto Muzik, Sandeep Mitta. Quantitative PET imaging of tryptophan accumulation in gliomas and remote cortex: correlation with tumor proliferative activity. Clinical nuclear medicine. vol 37. issue 9. 2012-12-13. PMID:22889771. |
pet studies with α[c-11]methyl-l-tryptophan (amt) have shown decreased serotonin synthesis based on a decrease of the unidirectional uptake rate (k-complex) in neuropsychiatric conditions such as autism and depression. |
2012-12-13 |
2023-08-12 |
Not clear |
| N V Selianina, Iu V Karakulov. [The effect of neurotrophic treatment on the activation of reparative processes in patients with acute traumatic brain injury]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 112. issue 5. 2012-12-10. PMID:22951781. |
the neurological and cognitive impairment, mild state anxiety and depression and increased levels of humoral serotonin, which depends on the severity of the injury, were identified in patients with mbi before treatment. |
2012-12-10 |
2023-08-12 |
Not clear |
| Shigeyuki Chak. [The potential of group II metabotropic glutamate receptor antagonists as a novel antidepressant]. Nihon shinkei seishin yakurigaku zasshi = Japanese journal of psychopharmacology. vol 32. issue 4. 2012-12-10. PMID:23012890. |
mglu2/3 receptor antagonists such as mgs0039 and ly341495 have been reported to exert antidepressant effects in animal models of depression including the forced swim test, tail suspension test, learned helplessness paradigm, olfactory bulmectomy model and isolation rearing model, and to enhance serotonin release in the prefrontal cortex and dopamine release in the nucleus accumbens. |
2012-12-10 |
2023-08-12 |
Not clear |